These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

419 related articles for article (PubMed ID: 32993388)

  • 1. Pharmacological management of Idiopathic Pulmonary Fibrosis: current and emerging options.
    Trachalaki A; Irfan M; Wells AU
    Expert Opin Pharmacother; 2021 Feb; 22(2):191-204. PubMed ID: 32993388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An update on current and emerging drug treatments for idiopathic pulmonary fibrosis.
    Trachalaki A; Sultana N; Wells AU
    Expert Opin Pharmacother; 2023; 24(10):1125-1142. PubMed ID: 37183672
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF).
    Aribindi K; Liu GY; Albertson TE
    Expert Rev Clin Pharmacol; 2024 Sep; 17(9):817-835. PubMed ID: 39192604
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of Idiopathic Pulmonary Fibrosis.
    Pleasants R; Tighe RM
    Ann Pharmacother; 2019 Dec; 53(12):1238-1248. PubMed ID: 31280590
    [No Abstract]   [Full Text] [Related]  

  • 5. Pamrevlumab for the treatment of idiopathic pulmonary fibrosis.
    Sgalla G; Franciosa C; Simonetti J; Richeldi L
    Expert Opin Investig Drugs; 2020 Aug; 29(8):771-777. PubMed ID: 32447983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of idiopathic pulmonary fibrosis with Nintedanib: an update.
    Wongkarnjana A; Yanagihara T; Kolb MR
    Expert Rev Respir Med; 2019 Dec; 13(12):1139-1146. PubMed ID: 31564185
    [No Abstract]   [Full Text] [Related]  

  • 7. Emerging drugs for the treatment of idiopathic pulmonary fibrosis: 2020 phase II clinical trials.
    Sgalla G; Lerede M; Richeldi L
    Expert Opin Emerg Drugs; 2021 Jun; 26(2):93-101. PubMed ID: 33998354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An updated safety review of the drug treatments for idiopathic pulmonary fibrosis.
    Sgalla G; Comes A; Richeldi L
    Expert Opin Drug Saf; 2021 Sep; 20(9):1035-1048. PubMed ID: 33881959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Do all patients with idiopathic pulmonary fibrosis warrant a trial of therapeutic intervention? A pro-con perspective.
    Moodley Y; Corte T; Richeldi L; King TE
    Respirology; 2015 Apr; 20(3):389-94. PubMed ID: 25727967
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nintedanib for Idiopathic Pulmonary Fibrosis.
    Tepede A; Yogaratnam D
    J Pharm Pract; 2019 Apr; 32(2):199-206. PubMed ID: 29017422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nintedanib for the treatment of idiopathic pulmonary fibrosis.
    Varone F; Sgalla G; Iovene B; Bruni T; Richeldi L
    Expert Opin Pharmacother; 2018 Feb; 19(2):167-175. PubMed ID: 29327616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Idiopathic Pulmonary Fibrosis].
    Prasse A
    Pneumologie; 2015 Oct; 69(10):608-14; quiz 615. PubMed ID: 26444136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pirfenidone for the treatment of idiopathic pulmonary fibrosis.
    George PM; Wells AU
    Expert Rev Clin Pharmacol; 2017 May; 10(5):483-491. PubMed ID: 28266906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The safety of new drug treatments for idiopathic pulmonary fibrosis.
    Fletcher S; Jones MG; Spinks K; Sgalla G; Marshall BG; Limbrey R; Richeldi L
    Expert Opin Drug Saf; 2016 Nov; 15(11):1483-1489. PubMed ID: 27532218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Existing and emerging treatments for idiopathic pulmonary fibrosis.
    Kolilekas L; Papiris S; Bouros D
    Expert Rev Respir Med; 2019 Mar; 13(3):229-239. PubMed ID: 30632421
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Idiopathic pulmonary fibrosis: Recent advances on pharmacological therapy.
    Spagnolo P; Maher TM; Richeldi L
    Pharmacol Ther; 2015 Aug; 152():18-27. PubMed ID: 25946646
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent evidence for pharmacological treatment of idiopathic pulmonary fibrosis.
    Covvey JR; Mancl EE
    Ann Pharmacother; 2014 Dec; 48(12):1611-9. PubMed ID: 25202034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of idiopathic pulmonary fibrosis in Australia and New Zealand: A position statement from the Thoracic Society of Australia and New Zealand and the Lung Foundation Australia.
    Jo HE; Troy LK; Keir G; Chambers DC; Holland A; Goh N; Wilsher M; de Boer S; Moodley Y; Grainge C; Whitford H; Chapman S; Reynolds PN; Glaspole I; Beatson D; Jones L; Hopkins P; Corte TJ
    Respirology; 2017 Oct; 22(7):1436-1458. PubMed ID: 28845557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The evolving pharmacotherapy of pulmonary fibrosis.
    Lota HK; Wells AU
    Expert Opin Pharmacother; 2013 Jan; 14(1):79-89. PubMed ID: 23265249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-life experiences in a single center: efficacy of pirfenidone in idiopathic pulmonary fibrosis and fibrotic idiopathic non-specific interstitial pneumonia patients.
    Feng H; Zhao Y; Li Z; Kang J
    Ther Adv Respir Dis; 2020; 14():1753466620963015. PubMed ID: 33070705
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.